BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

by BIO-RAD LABORATORIES  · Based in United States → — Advanced Multiplex Immunoassay System with AI-Powered Medical Decision Support for Autoimmune and Infectious Disease Diagnostics
Infectious Disease Laboratory Medicine Rheumatology

Contact for pricing
Regulatory Status Disclosed

Overview

The BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM is a fully automated, random access multiplex immunoassay system designed for clinical laboratories. It is not an AI tool for a physician directory, but rather a sophisticated in vitro diagnostic (IVD) system with integrated software to aid in the diagnosis of systemic autoimmune diseases and other conditions.

The system utilizes multiplex bead technology to simultaneously detect and differentiate multiple autoantibodies and other analytes from a single patient sample, improving workflow efficiency and turnaround time compared to traditional single-analyte methods. The Medical Decision Support Software (MDSS) is an optional feature that employs an interpretive software algorithm, specifically a k-Nearest Neighbor (kNN) algorithm, to associate patient antibody results with predefined profiles correlated with specific connective tissue diseases such as Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Sjögren’s Syndrome (SS), Scleroderma (Systemic Sclerosis), and Polymyositis. This provides clinicians with valuable, actionable information to support faster diagnoses and improved patient outcomes.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fully automated random access system
  • Multiplex immunoassay technology (up to 25 analytes per tube)
  • Medical Decision Support Software (MDSS) with interpretive algorithm (kNN)
  • High throughput (up to 1200-1400 patient results per hour)
  • Simultaneous detection of multiple autoantibodies and analytes
  • Reduced hands-on time and labor costs
  • Internal quality control beads for reliable results
  • Consolidation of autoimmune, infectious disease, and vitamin D testing
  • Interfaces with Laboratory Information Systems (LIS)
  • Aids in diagnosis of systemic autoimmune diseases

Use Cases

  • Screening and diagnosis of systemic lupus erythematosus (SLE)
  • Diagnosis of mixed connective tissue disease (MCTD)
  • Diagnosis of Sjögren's syndrome (SS) and scleroderma
  • Detection of autoantibodies for vasculitis, rheumatoid arthritis, and celiac disease
  • Testing for infectious diseases (e.g., HIV, Syphilis, EBV, ToRC)
  • Vitamin D testing

What Physicians Need to Know

Evidence Base (guidelines, literature scope)
The Medical Decision Support Software (MDSS) uses an interpretive algorithm trained with over 15,000 test results from a diverse cohort of over 1400 clinically characterized patients. The BioPlex 2200 ANA Screen is intended to aid in the diagnosis of systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Sjögren's Syndrome (SS), Scleroderma (Systemic Sclerosis), Polymyositis, Dermatomyositis, and CREST Syndrome.
Clinical Validation Studies
The BioPlex 2200 ANA Screen with MDSS was the first FDA-cleared autoimmune product with interpretive software that correlates patient antibody results with specific autoimmune diseases. Studies have shown the BioPlex 2200 ANA Screen alone offers similar or superior clinical performance compared to traditional HEp-2 IFA for initial ANA testing. The specificity of the BioPlex 2200 ANA Screen analysis of 13 different analytes is comparable to the ELISA ANA screening test. Intra-assay precision was between 2.5 – 4.7% CV and inter-assay precision between 6.8 – 8.6% CV, demonstrating excellent reproducibility. Dilution linearity for the dsDNA assay was confirmed with a correlation coefficient greater than 99.9% when compared to the WHO W/o 80 external standard.
Clinical Workflow Integration
The BioPlex 2200 System is a fully automated, random access multiplex system that allows for simultaneous detection of multiple autoantibodies in one reaction tube. It can generate up to 14 individual results per test, providing up to 1,400 results per hour, which streamlines workflow and eliminates separate follow-up testing. The system offers bi-directional LIS connectivity. Observational workflow studies have shown the BioPlex 2200 System required significantly less total operating time and manual labor compared to other systems for ANA testing.
Decision Audit Trail
The eFlex™ Software package includes tools for "add-on" of new test orders from previously run patient samples and creation of custom ENA panels.
Physician Tip

The BioPlex 2200 ANA Screen with MDSS provides a comprehensive autoantibody profile to aid in the diagnosis of various systemic autoimmune diseases. The MDSS can associate positive ANA result profiles with specific connective tissue diseases, offering valuable interpretive information. This system can help streamline the diagnostic process by providing multiple results from a single sample and may reduce the need for extensive follow-up testing. Consider the MDSS associations in conjunction with clinical symptoms and other laboratory findings for a complete patient assessment. The system's high throughput and automation can lead to faster turnaround times, potentially improving patient care.

The BioPlex 2200 System offers bi-directional LIS connectivity for seamless integration into laboratory information systems. The multiplex technology allows for consolidation of autoimmune and infectious disease testing onto a single high-throughput analyzer.

Details

Category Clinical Decision Support & Reference, Lab & Diagnostics
Pricing Contact for pricing
DeploymentOn-premise (clinical laboratories, hospitals, national reference laboratories, public health laboratories)
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Infectious Disease, Laboratory Medicine, Rheumatology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2005-10-27K043341 510(k)BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

The BioPlex 2200 ANA Screen uses multiplex technology to simultaneously detect up to 13 different autoantibodies of clinical significance in a single sample. The optional MDSS then uses an interpretive algorithm, trained with over 15,000 test results from clinically characterized patients, to associate these antibody profiles with specific autoimmune diseases like Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Sjögren's Syndrome (SS), Scleroderma, and Polymyositis.
This system offers several advantages over traditional methods like IFA or ELISA, including full automation, multiplex technology for simultaneous detection of multiple autoantibodies, and faster turnaround times. It can provide up to 14 individual results per test, streamlining workflow and potentially reducing the need for separate follow-up testing. The MDSS also provides simplified interpretation of complex antibody profiles.
It's important to consider ANA Screen and MDSS results in conjunction with the patient's clinical presentation and other laboratory findings. Patients with Rheumatoid Arthritis may show an SLE association or positive antibodies for dsDNA or Chromatin, requiring cautious interpretation. Additionally, MDSS interpretations of "Negative" or "No Association" do not definitively rule out autoimmune disease. SLE patients undergoing steroid or immunosuppressant therapy may also have false-negative results.
Yes, the BioPlex 2200 ANA Screen and the Medical Decision Support Software (MDSS) have received marketing clearance from the U.S. Food and Drug Administration (FDA). The MDSS was the first product of its kind to be FDA-cleared for correlating patient antibody results with specific autoimmune diseases.
The BioPlex 2200 ANA Screen detects a panel of clinically relevant autoantibodies including dsDNA (quantitative), Chromatin, Ribosomal Protein, SS-A (52 and 60), SS-B, Sm, SmRNP, RNP (A and 68), Scl-70, Jo-1, and Centromere B.
The MDSS utilizes an interpretive algorithm to analyze the individual antibody results from the ANA Screen. It can suggest possible disease associations with systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Sjögren's Syndrome (SS), Scleroderma (Systemic Sclerosis), and Polymyositis.

Related Tools

Stanford University
Stanford University
Clinical Decision Support & Reference
Stanford Online's "AI in Healthcare" program provides a comprehensive overview of artificial intelligence's applications and implications within the medical field.
RADIN Health
RADIN Health
Clinical Decision Support & Reference
RADINA is an AI-powered platform by RADIN Health designed to optimize radiology workflows, enhance diagnostic accuracy, and streamline reporting.
Med-PaLM 2
Google
Clinical Decision Support & Reference
Med-PaLM 2 is a large language model from Google, fine-tuned for healthcare to provide high-quality answers to medical questions and support clinical decision-making.
Pacmed Critical Discharge
Pacmed
Clinical Decision Support & Reference
Pacmed Critical Discharge is an AI tool that predicts the probability of death or readmission within seven days of ICU discharge, providing explainable insights for physicians.
AiZtech Labs
AiZtech Labs
Clinical Decision Support & Reference
AiZtech Labs provides enterprise-grade AI solutions for healthcare, focusing on operational efficiency, diagnostic accuracy, and patient care workflows for providers and health systems.
Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-03 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.